

INDEX

A

Acyl-CoA.....207, 214
 Adduct formation.....24, 306, 307
 Adipose tissue.....226, 230
 AE. *See* Anion exchange (AE)
 Alcohols.....4, 31, 109, 131, 138, 143, 144, 251, 269
 Aldehydes.....103, 144, 269
 Alignment.....20, 55, 89, 94, 95, 103,
 115, 123, 255–257, 260, 261, 334
 Alkaloids.....30
 Alkylation.....138
 Ambient mass spectrometry.....275, 299
 Amines.....15, 20, 31, 87, 93, 108,
 120, 128, 129, 204, 307
 Amino acids.....15, 20, 24, 31, 43–45, 47,
 56, 57, 60, 67, 93, 104, 108, 120, 137–144, 152, 153,
 158, 159, 163, 172, 181, 300
 Analysis of variance (ANOVA).....38, 58
 Anion exchange (AE).....49, 51, 53, 54, 57, 58, 68
 ANOVA. *See* Analysis of variance (ANOVA)
 ANP. *See* Aqueous normal phase (ANP)
 APCI. *See* Atmospheric pressure chemical ionization (APCI)
 APPI. *See* Atmospheric pressure photoionization (APPI)
 Aqueous normal phase (ANP).....30–35
 Area under the ROC curve (AUROC).....346, 348, 349
 Aromatic hydrocarbons.....31
 Atmospheric pressure chemical ionization (APCI).....6, 276
 Atmospheric pressure photoionization (APPI).....6
 AUROC. *See* Area under the ROC curve (AUROC)
 Autoscaling.....115, 258, 260, 335

B

Background electrolyte (BGE).....109, 113, 114
 BALF. *See* Bronchoalveolar lavage fluid (BALF)
 Baseline correction.....89, 212, 215, 216, 255–257
 Benjamini–Hochberg procedure.....56, 339
 Benjamini–Hochberg–Yekutieli procedure.....339
 BGE. *See* Background electrolyte (BGE)
 Bias.....18, 24, 47, 95, 122, 148, 238, 245, 261, 276, 348
 Bile acids.....233–246
 Biofluids.....112, 127, 133, 153,
 155, 156, 163, 164, 208, 265, 333, 335
 Bioinformatics.....49–51, 55–60, 153, 282

Biomarker.....9, 10, 15, 17, 22, 23, 49, 60, 71, 112, 121, 234,
 333, 334, 336, 337, 339–342, 344, 348, 349, 351
 discovery.....15, 90, 129, 148
 selection.....334, 336, 344, 348, 349, 351
 Biomass.....31
 Biopsy tissue.....155, 163
 Biostatistics.....49–51, 55–60
N,O-Bis(trimethylsilyl)trifluoroacetamide
 (BSTFA).....87, 90, 91, 93
 Bonferroni.....339
 Brain.....8, 85, 208, 211, 224, 227,
 300, 307, 309, 321, 322, 3020–305
 Breath samples.....251–254
 Bronchoalveolar lavage fluid (BALF).....155
 BSTFA. *See N,O*-Bis(trimethylsilyl)trifluoroacetamide
 (BSTFA)

C

Cancer.....6, 8, 147, 148, 152, 300,
 309, 339, 341–343, 346–350
 breast.....6, 337, 338
 colon.....234
 liver.....234, 339, 341–343, 346–350
 Capillary.....19, 34, 53, 54, 99, 100, 102, 109,
 110, 113, 121, 122, 228, 240, 277–279, 284, 293, 302,
 307, 308, 314
 Capillary electrophoresis (CE).....5, 9, 49, 90, 107–123, 138
 Cardiovascular diseases.....6
 Carryover.....9, 93, 104, 181, 197, 286
 CE. *See* Capillary electrophoresis (CE); Cholesterol esters
 (CE)
 Cell walls.....158
 Cerebrospinal fluid.....211
 Chemical derivatization.....5, 16, 128, 144,
 151, 277, 278, 282
 Chemical ionization (CI).....141, 277
 Chemometric analysis.....251–261
 Chiral chromatography.....224, 228
 Chiral HPLC.....228, 230
 Chloroformate.....138, 141, 144
 Chloroformate derivitization.....137–144
 Chloropropamide.....17–19
 Cholesterol.....44, 50, 204, 233, 234
 Cholesterol esters (CE).....204, 306

Cholic acid233, 237
 CI. *See* Chemical ionization (CI)
 Citric acid cycle43, 67
 Classification9, 25, 55, 93, 115, 203,
 212, 228, 252, 282, 334, 336, 337, 339–349, 351
 Classification trees346
 Classifier346
Clostridium acetobutylicum84, 90, 91
¹³C NMR130
 Column switching49, 53, 178, 181, 192, 193
 Confounding factors9, 252, 261
 Conjugated bile acids233, 234, 238, 240, 243
 Correlation3, 9, 10, 38, 55, 57–60, 68, 70, 206, 240,
 257–259, 300, 309, 337, 340, 341, 343, 344, 351
 Correlation optimized warping (COW)257
 COW. *See* Correlation optimized warping
 Cross validation9, 25, 115, 260,
 334, 341, 342, 344, 348, 349
 Cryosectioning315, 319–322, 326, 327

D

Dansylation127–135
 Dansyl chloride (DnsCl)128–133, 135
 DART. *See* Direct analysis in real time (DART)
 Data analysis25, 55–60, 85, 89–90,
 92–94, 100, 112, 115, 143, 144, 150, 151, 195, 255,
 258, 260, 268, 282, 304–305, 334, 336
 Databases5, 23, 29, 36, 37, 39–40, 44,
 45, 49, 51, 55, 56, 60, 63–64, 67, 70, 102–104, 116,
 150, 160, 212, 215, 218, 261, 269, 283, 284, 305, 334
 DBS. *See* Dried blood spot (DBS)
 Decision function345
 DESI. *See* Desorption electrospray ionization (DESI)
 Desolvation20, 240, 300
 Desorption electrospray ionization (DESI)8, 276,
 291–296, 299–309, 314
 Diabetes3, 122, 147, 251
 Diagnostics3, 4, 8, 15–16, 60, 131,
 137, 207, 252, 300, 309
 Diet69–70, 109, 112, 233, 251, 333, 343
 Differential isotopic labeling127
 Direct analysis57, 292
 Direct analysis in real time (DART)8, 275–288, 337, 338
 Direct infusion153, 157, 204–205, 209, 276
 DnsCl. *See* Dansyl chloride (DnsCl)
 Docosanoids221, 223
 Dried blood spot (DBS)291–296
 Drug metabolites178, 291, 314
 Dummy matrix341

E

EESI. *See* Extractive electrospray ionization (EESI)
 EI. *See* Electron impact (EI)
 Eicosanoids221, 223

Electron impact (EI)5, 88, 143, 151
 Electrospray ionization (ESI)5, 16, 108, 110,
 128, 180, 237, 240, 276, 277, 300, 308, 309, 314
 Endogenous metabolites15, 16, 171, 172, 178, 181
 Energy metabolism43, 70, 234
 Environmental chemicals64, 65
 Error rate348, 349
 ESI. *See* Electrospray ionization (ESI)
 Esters215, 269
 Exogenous metabolites269, 313
 Extractive electrospray ionization (EESI)8

F

False discovery rate (FDR)56, 58–60, 103, 339
 Fasting7–8, 10, 16, 31, 87,
 92, 108, 113, 131, 171, 252, 348
 Fast scanning83, 88
 Fatty acid oxidation43–44
 FDR. *See* False discovery rate (FDR)
 Fingerprinting4, 93, 108, 112, 113, 116, 122, 343
 Flavonoids30
 Formic acid17, 32, 34, 50, 53, 68, 77, 109,
 112, 113, 122, 131, 132, 179, 224, 226, 237, 292, 296
 Fourier transform ion cyclotron resonance
 (FT-ICR)6, 45, 48, 49, 129,
 131, 132, 149, 153, 277
 Fourier transform mass spectrometry
 (FT-MS)43–71, 147–164
 Fragmentation pattern23, 95, 108, 160
 FT-MS. *See* Fourier transform mass spectrometry (FT-MS)

G

Gangliosides204, 309
 Gas chromatography (GC)4–6, 9, 16, 48,
 49, 83–85, 90, 92, 99–102, 104, 138, 139, 141, 151,
 160, 223, 252, 253, 255, 257, 266–268, 334
 Gas chromatography mass spectrometry
 (GC-MS)4–6, 99, 108, 137–144, 147–164, 223,
 251–261, 263, 265, 266, 269, 272, 276, 333, 334, 336
 GC. *See* Gas chromatography (GC)
 GC×GC-TOF MS83–95, 99–105
 GC-MS. *See* Gas chromatography mass spectrometry
 (GC-MS)
 Gender333
 Genetic markers29, 31
 Genomics16, 30, 38
 Global metabolic profiling6, 15–25
 Glutathione (GSH)44, 66, 76, 78
 Glycerophosphocholines (PC)307, 309
 Glycerophosphoethanolamines (PE)309
 Glycerophosphoglycerols (PG)309
 Glycerophosphoinositols (PI)149, 306, 309
 Glycolysis163
 GSH. *See* Glutathione (GSH)

H

Headspace265–272
 Hepatitis C 339–341, 346, 349
 H&E staining.....300, 309
 High resolution MS 4, 43–71, 129, 149, 221–231, 276, 293
 Hilbert space345
 HILIC. *See* Hydrophilic interaction liquid chromatography (HILIC)
 Histology..... 300, 301, 309
 Histopathology.....8, 313
¹H Nuclear magnetic resonance (NMR) 16, 158, 164
 Hydrocarbons 30, 31, 269
 Hydrophilic interaction liquid chromatography (HILIC) 5, 24, 108, 197

I

Identification 4, 6, 16–18, 20, 23, 29, 30, 36, 37, 39, 47–49, 55–57, 59–60, 63, 67, 70, 75–76, 85, 87, 94, 100–105, 108, 115–120, 128, 148, 150, 151, 160, 203, 204, 206, 207, 213–216, 218, 223, 224, 228–230, 234, 258, 261, 269, 271, 275, 276, 300, 304, 308, 309, 320, 328, 334–337, 340
 Imaging 8, 276, 302–304, 307–309, 313–328
 Inborn errors of metabolism.....6
 In silico.....20, 35
 Internal standard (IS)9, 17–19, 21, 23, 32, 33, 35, 37, 50, 52, 53, 69, 109, 112–14, 122, 138–140, 142, 154, 181, 191, 192, 204–206, 208, 209, 211, 216, 218, 224, 234, 240, 292, 335
 Intrasource separation.....205, 206
 Ion suppression..... 5, 24, 37, 85, 128, 204, 205
 IS. *See* Internal standard (IS)
 Isotope labeled internal standards.....7
 Isotope tag.....128
 Isotope tracer148, 149
 Isotopic labeling reagent.....151
 Isotopologue148, 150–153, 160–162, 206

K

Ketones..... 87, 92, 103, 269
k-fold cross validation.....342, 349
 Kidney disease 6, 8, 335
 Krebs cycle.....148

L

Latent variable (LV).....341
 LC. *See* Liquid chromatography (LC)
 LC-MS. *See* Liquid chromatography mass spectrometry (LC-MS)
 Leave one out cross validation..... 9, 341, 349
 Leukotrienes (LT)221
 Linear ion trap (LIT) 6, 226, 302, 305

Lipid analysis.....164, 204, 205, 207, 212, 216, 218, 223, 300, 306–307, 314
 Lipid mediators 221, 223, 224, 227–230
 Lipidomics.....52, 203–219, 221–231, 306
 Lipids 8, 30, 85, 107, 113, 116, 142, 149, 153, 156–158, 164, 203–218, 221–231, 233, 299–309, 313, 314
 Liquid chromatography (LC) 4–6, 9, 16, 17, 19, 20, 24–25, 30–34, 47–49, 51, 53, 75, 85, 90, 126, 138, 180, 223, 224, 227–228, 237, 239, 334
 Liquid chromatography mass spectrometry (LC-MS)5, 6, 16, 17, 24–25, 29–40, 50, 51, 53–54, 75–79, 85, 108, 127–135, 171–198, 204, 205, 223–226, 234, 237, 239–240, 291, 296, 333–335, 339
 LIT. *See* Linear ion trap (LIT)
 Loading plot.....22–23, 115, 337, 338, 341
 Logistic regression.....8, 9, 22, 334, 336, 341, 343–345, 349–351
 Log likelihood function.....344
 Log scaling336
 LPE. *See* LysoPE (LPE)
 LT. *See* Leukotrienes (LT)
 LV. *See* Latent variable (LV)
 LysoPE (LPE)204–205

M

MALDI. *See* Matrix assisted laser desorption ionization (MALDI)
 Manhattan plot.....56
 Mapping populations29–40
 Mass spectral matching 94, 95, 102, 104
 Mass spectrometry (MS)3–10, 16, 17, 19–21, 34–35, 37, 39, 45, 48, 49, 51, 53, 54, 59, 69, 108–110, 112–116, 121, 128, 129, 132–133, 138, 139, 141, 143, 144, 147–149, 151, 152, 154, 155, 157, 161, 164, 180, 181, 193, 197, 204, 206, 209, 211, 212, 216, 218, 223, 226, 228, 234, 237–241, 245, 252, 253, 255, 257, 268, 275–277, 279–281, 283, 285, 287, 288, 293–295, 299–302, 304, 305, 307–309, 315, 321, 323, 327, 333–335, 343, 351
 Mass spectrometry imaging (MSI)..... 313–316, 323–324
 Matrix assisted laser desorption ionization (MALDI) 309, 314, 315, 320–328
 Matrix effects.....113
 MCCV. *See* Monte Carlo cross validation (MCCV)
 Mean centering21, 115, 334, 335, 337
 Metabolic fingerprinting 4, 107–123, 276–277
 Metabolic fluxes6
 Metabolic pathways.....6, 24, 39, 44, 45, 49, 63, 120, 147–164, 171–172, 333, 336, 351
 Metabolic trait29, 31, 38
 Metabolite extraction 4, 5, 18, 37, 44, 75, 78, 87, 91, 100, 101, 149, 155, 179, 194–196, 198, 277, 282
 Metabolite flux analysis223

- Metabolite profiling 6, 9, 25, 31, 38, 75–79, 108, 138, 143, 144, 148, 153, 155–157, 171–198, 275–288
- Metabolomics 3–10, 15–18, 22, 24, 25, 30, 40, 43–71, 75, 83–89, 91, 92, 94, 107, 108, 112, 114–116, 119–122, 127–135, 144, 147–152, 162, 163, 171, 192, 265–272, 275, 276, 280, 282–284, 313, 333–351
- Methoximation 87, 93
- Mitochondria 43–45, 47, 49–52, 56–60, 63–65, 67, 68, 70, 71
- dysfunction 60, 70
- isolation 49, 51, 69
- metabolites 49, 52–54, 58, 61, 64, 67, 70
- metabolome 47, 49, 56, 60, 64
- Monte Carlo cross validation (MCCV) 9, 334, 342, 348–351
- Morphology 300, 306, 309, 321
- Mouse brain 300, 302–305, 307
- Mouse liver metabolomics 45, 50, 56, 63, 64, 99–105
- MRM. *See* Multiple reaction monitoring (MRM)
- MS. *See* Mass spectrometry (MS)
- MSI. *See* Mass spectrometry imaging (MSI)
- MS/MS. *See* Tandem mass spectrometry (MS/MS)
- MSⁿ 7, 49–51, 56, 57, 154
- MSTFA. *See* *N*-Methyl-*N*-(trimethylsilyl)trifluoroacetamide
- MTBSTFA. *See* *N*-Methyl *N*(*tert*-butylsilyl)trifluoroacetamide
- Multidimensional MS 204–219
- Multiple comparison 56, 121, 337–339
- Multiple reaction monitoring (MRM) 141, 143, 144, 171–198, 234, 238, 240, 245, 293–296
- Multiplexed chromatography 269
- Multivariate statistical analysis 4, 8, 16, 18, 21–22, 25, 333–336, 351
- Muricholic acid 233
- Muscle tissue 224, 226
- N**
- Nanospray 212, 216, 218
- Nanostructure-initiated mass spectrometry (NIMS) 313–328
- NEFA. *See* Non-esterified fatty acids (NEFA)
- Negative ionization 20, 34, 37, 39, 115, 178, 181, 228, 339
- Neutral loss scanning (NLS) 206, 212, 215, 216, 219
- NIMS. *See* Nanostructure-initiated mass spectrometry (NIMS)
- NIMS chip 315–321, 323, 325–328
- N*-Methyl *N*(*tert*-butylsilyl)trifluoroacetamide (MTBSTFA) 93, 104, 151, 154, 159
- N*-Methyl-*N*-(trimethylsilyl)trifluoroacetamide (MSTFA) 93, 100, 104, 277, 278
- NMR. *See* Nuclear magnetic resonance (NMR)
- N,O*-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) 87, 90–93
- Noise 21–22, 50, 55, 57, 69, 84, 89, 99, 114–115, 207, 215, 219, 245, 260, 323, 328, 335, 343, 345
- Non-esterified fatty acids (NEFA) 204, 208
- Non-targeted metabolomics 85
- Normalization 21, 37, 52, 55–56, 89, 103–105, 109, 112, 115, 122, 155, 161, 162, 216, 258, 260, 261, 269, 282, 334, 335
- Normalization, creatinine 112, 122, 335
- Nuclear magnetic resonance (NMR) 4, 16, 75–79, 130, 147–149, 151, 153, 157, 158, 164, 206, 275, 337
- Nucleic acids 172, 180
- Nucleic bases 180
- Nucleosides 24, 181
- Nucleotides 56, 57, 60, 67, 153, 157, 181
- Null hypothesis 337–339
- Nutrition 6, 16, 69
- O**
- Oligosaccharides 30
- Omega-3 fatty acids 221
- Omega-6 fatty acids 221
- OPLS-DA. *See* Orthogonal projection to latent structure-discriminant analysis (OPLS-DA)
- Orbitrap 6, 48, 49, 51, 54, 63, 69, 152, 226, 277, 300–304, 307, 308
- Organic acids 15, 20, 31, 119–120, 137–144, 152, 154, 158, 159, 172, 181
- Orthogonal projection to latent structure-discriminant analysis (OPLS-DA) 22, 59, 60, 115
- Orthogonal signal correction (OSC) 59, 343
- Over-fitting 334, 340, 341, 351
- P**
- Pareto scaling 21, 115, 258, 260, 335
- Partial least squares (PLS) 8–9, 22, 25, 38, 59, 94, 258–259, 282, 334, 336, 337, 341, 343
- Partial least squares discriminant analysis (PLS-DA) 8, 9, 22–23, 25, 115, 258–259, 336, 338, 341–344, 346–349
- PC. *See* Glycerophosphocholines (PC)
- PCA. *See* Principal component analysis (PCA)
- PE. *See* Glycerophosphoethanolamines (PE)
- Peak alignment 20, 55, 89, 95, 103, 255, 256, 334
- Peak deconvolution 20, 89, 95
- Peak picking 20, 129, 255–257, 334
- Pearson's correlation 38, 55, 257
- Penalized logistic regression 336, 344
- PG. *See* Glycerophosphoglycerols (PG)
- Phenotype 29–40, 85, 251
- Phenylpropanoids 30
- Phospholipid 300, 323
- PI. *See* Glycerophosphoinositols (PI)
- Plant cultivars 64

Plant material 31, 39, 85
 Plasma 17–19, 45, 49, 60–64, 66–67, 71, 108, 109, 111–113, 122, 155, 179, 192, 194, 195, 198, 211, 224, 226, 227, 231, 238, 244, 280–281, 285, 291, 292
 Plasmalogens 204, 207
 Plasticizers 64, 269
 PLS. *See* Partial least squares (PLS)
 PLS-DA. *See* Partial least squares discriminant analysis (PLS-DA)
 Polarity 31, 99, 108, 154, 164, 178, 181, 192, 197, 204, 218, 277, 306–307
 Polyunsaturated fatty acids (PUFA) 221–231
 Pooled quality control sample 19
 Positive ionization 20, 34, 37, 39, 115, 178, 197, 339
 Power 6, 114, 152, 160, 161, 195, 223, 228, 315, 317, 318, 337–340, 348
 Precursor ion 7, 20, 57–59, 192, 240
 Precursor ion scanning (PIS) 206, 212
 Principal component analysis (PCA) 8, 9, 22, 25, 76, 94, 108, 115, 258, 260, 334, 336–338, 341, 351
 Probe mode DART 277
 Product ion 7, 48, 57–59, 192, 228, 230, 240
 Propanol 31
 Prostaglandins (PG) 208, 221
 Protein precipitation 17, 19, 79, 131, 142, 155, 157, 277, 278, 282, 291
 PUFA. *See* Polyunsaturated fatty acids (PUFA)
p-value 56, 102, 338, 339, 341, 348

Q

Q. *See* Quadrupole (Q)
 QC. *See* Quality control (QC)
 QIT. *See* Quadrupole ion trap (QIT)
 Q-TOF. *See* Quadrupole-TOF (Q-TOF)
 Quadrupole (Q) 6, 44, 121, 143, 218, 240
 Quadrupole ion trap (QIT) 6
 Quadrupole-TOF (Q-TOF) 6, 15–25, 121, 277, 279, 283
 Quality control (QC) 19–21, 33, 50, 55, 57, 69, 114, 115, 122, 143, 157, 191, 192, 224–226, 240, 245, 293, 295, 296, 335
 Quantification 5, 7, 23, 48, 55, 85, 94, 100, 101, 103, 127, 128, 130, 144, 150, 152, 155, 160, 192, 195, 203–207, 212–217, 219, 223, 229, 230, 234, 238, 241–242, 245, 269, 314
 Quantitative analysis 4–7, 137–144, 224, 292
 Quantitative trait locus 29
 Quench 78, 85, 87, 91, 92, 130, 132, 155, 156, 164, 239

R

Random forest 38, 259, 334, 341, 346–347
 Randomization 18, 20, 33, 37, 122

Rat plasma 179, 192, 194, 195, 198
 Rat serum 116, 120
 Receiver operating characteristic (ROC) 334, 345–349
 Regression models 334, 343, 344, 349–351
 Relative standard deviations (RSDs) 19
 Reverse phase 5, 17, 49, 51
 ROC. *See* Receiver operating characteristic (ROC)
 RSDs. *See* Relative standard deviations (RSDs)

S

Saliva 155
 Sample preparation 9, 16–19, 24, 25, 37, 49, 52–53, 67, 75–79, 85, 86, 91, 108, 138, 140, 148, 195, 196, 207, 210, 226–227, 237, 239, 265–267, 276, 292, 315, 321
 Scaling 115, 142, 149–150, 164, 196, 203, 258, 316, 334–337
 Score plot 22, 337, 338, 341, 342
 Secondary metabolites 30, 39, 300
 Serum 17–19, 77, 78, 109, 112–113, 116, 120, 122, 131–132, 135, 211, 233–245, 276–279, 282–287, 337, 339
 Shotgun lipidomics 203–219
 Signal 9, 16, 21, 48, 55, 59, 69, 75, 76, 79, 84, 95, 114, 115, 163, 181, 193, 212, 215, 234, 282–286, 296, 302, 307, 308, 318, 319, 321–325, 327, 328, 335, 336, 340, 343
 SILIS. *See* Stable isotope labeled internal standard (SILIS)
 Silylation 87, 92, 93, 138, 144, 282
 Similarity score 102
 SIRM. *See* Stable isotope resolved metabolomics (SIRM)
 SM. *See* Sphingomyelins (SM)
 Solid phase microextraction (SPME) 265–272
 Spearman's rank correlation 38
 Sphingolipids 204, 207, 212, 218
 Sphingomyelins (SM) 206–208, 213, 307, 309
 SPME. *See* Solid phase microextraction (SPME)
 Spray geometry 302
 ST. *See* Sulfatide (ST)
 Stable isotope 48, 50, 52, 148, 149, 152
 Stable isotope coded derivatization reagent 138, 139
 Stable isotope labeled internal standard (SILIS) 7
 Stable isotope resolved metabolomics (SIRM) 148–151, 153, 162, 163
 Starch 31
 Steroids 44, 45, 233
 Student's *t*-test 25, 38, 85, 115, 337
 Sugar phosphates 181
 Sugars 15, 20, 24, 31, 138, 144, 172, 181, 191, 300
 Sulfatide (ST) 207, 214, 304–305, 309
 Support vector machines (SVMs) 22, 334, 341, 345, 349–351
 SVMs. *See* Support vector machines (SVMs)

T

TAG. *See* Triacylglycerols (TAG)
 Tandem mass spectrometry (MS/MS) 6, 7, 20, 23,
 24, 34–37, 39, 40, 47, 48, 51, 57, 59, 70, 108,
 137–144, 149, 206–207, 212, 216, 218, 219, 223,
 228, 230, 237, 238, 276, 291, 300, 305, 308, 309,
 327, 328, 334
 Targeted analysis24, 36–37, 44, 45, 48,
 85, 139, 150, 151, 160, 235
 Targeted metabolomics..... 6, 31, 47, 83–95,
 127, 128, 148, 163, 171–198, 265, 272, 339
 Testing set259, 260, 342, 344, 348, 349
 Thermal modulator 84, 88, 90, 92, 93, 99, 102
 Thromboxanes (TX).....221
 Time of flight (TOF)6, 48, 99, 109, 115,
 121, 253, 277, 279
 Tissue 4, 8, 10, 17, 19, 31–33,
 39, 49, 64, 77–79, 86, 100, 101, 108, 121, 149, 153,
 154, 158, 160, 163, 164, 207–211, 224, 226, 227,
 233–245, 275, 300–303, 305–309, 313, 315,
 319–324, 326–328, 339
 imaging300, 307, 320, 322, 324, 328
 sections300–303, 305, 306, 308,
 309, 313, 320, 321, 327, 328
 TMCS. *See* Trimethylchlorosilane (TMCS)
 TMS. *See* Trimethylsilyl (TMS)
 TOF. *See* Time of flight (TOF)
 Total ion electropherogram116, 120
 Toxicity..... 4, 6, 16, 70, 195, 234, 291, 343
 Training set.....259, 260, 344, 348, 349
 Transmission mode DART281
 Triacylglycerols (TAG)..... 204, 208, 230, 306
 Trimethylchlorosilane (TMCS)87, 90, 91, 100, 277, 278

Trimethylsilyl (TMS)..... 84, 87, 88, 90, 92, 93, 276
 Triple quadrupole 6, 45, 121, 138,
 139, 141, 180, 197, 218
Triticum aestivum L.29–30
 Two sample *t*-tests..... 334, 336–339
 TX. *See* Thromboxanes (TX)

U

Ultrahigh performance liquid chromatography
 (UPLC) 15–25, 233–245
 UPLC. *See* Ultrahigh performance liquid chromatography
 (UPLC)
 Urine 3, 4, 17–19, 85, 86, 108,
 109, 112, 113, 115, 122, 129, 131–135, 155, 224, 226,
 265–272, 333, 335

V

Validation10, 25, 47, 56, 238, 259,
 260, 334, 340, 342, 348–351
 Variable selection25, 334, 336–341, 344, 345, 351
 Variable selection, stepwise.....344
 Variance 9, 37, 38, 115, 258, 260,
 280, 281, 335–337, 341, 344, 345, 348
 Variance scaling 115, 335
 Vector length normalization335
 Vitamin D44
 VOC. *See* Volatile organic compound (VOC)
 Volatile organic compound (VOC) 251–261, 265–272

W

Weight plot341
 Welch's *t*-test337
 Wilcoxon–Mann–Whitney test.....337